U.S. markets open in 3 hours 9 minutes

Odyssey Group International, Inc. (ODYY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6600-0.0400 (-5.71%)
At close: 3:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7000
Open0.7750
BidN/A x N/A
AskN/A x N/A
Day's Range0.6100 - 0.7750
52 Week Range0.2000 - 2.0000
Volume65,106
Avg. Volume97,525
Market Cap65.882M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-0.0440
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Odyssey Group International Announces Formation of Scientific Advisory Board
    GlobeNewswire

    Odyssey Group International Announces Formation of Scientific Advisory Board

    Irvine, CA, April 14, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the formation of a Scientific Advisory Board (SAB) with the appointment of leading experts in the fields of neurology, cardiology and preclinical drug development. The SAB will guide and advise the Company as it advances its proprietary platforms developing innovative technologies that address unmet medical needs. “We are proud to have such an accomplished group of scientific and clinical experts as inaugural members of our Scientific Advisory Board,” said Michael Redmond, President and Chief Executive Officer of Odyssey Group International. “Their scientific perspectives will provide value in supporting the development of our product portfolio, including our drug candidate, PRV-002 intended to treat concussion. Our management team is eager to leverage this group’s expertise to optimize our R&D and clinical activities.” Founding members of the SAB include: James P. Kelly, MA, MD, FAAN, FANA – Dr. Kelly is the Executive Director of the Marcus Institute for Brain Health (MIBH) and Professor of Neurology at the University of Colorado Anschutz Medical Campus in Aurora, CO. The MIBH is a specialized treatment program funded by the Marcus Foundation to care for US military Veterans with persistent symptoms of TBI. He is also National Director of the Gary Sinise Foundation Avalon Network TBI Medical Programs for which the MIBH serves as the clinical coordinating center. His immediate past position was Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center in Bethesda, MD. As its founding Director, he led the creation of an innovative interdisciplinary team of healthcare professionals who blended high-tech diagnosis and treatment with complementary and alternative medical interventions in a holistic, integrative approach to the care of US military personnel with the complex combination of TBI and psychological conditions such as post-traumatic stress, depression and anxiety. In this role, Dr. Kelly was frequently called upon by leaders of the Military Health System in the Pentagon, the US Congress, the Department of Veterans Affairs and numerous military facilities in the continental US and abroad. He twice traveled to Afghanistan to advise and assist at military hospital programs and forward operating base medical units. Dallas C. Hack, MD, MPH, FACMPH, COL, US Army – Dr. Dallas C. Hack graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He entered active duty in September 1987, to accept a position in clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and completed a residency in General Preventive Medicine in 1995. He also has a MPH from Johns Hopkins University, a MSS from the US Army War College, a CPE from the Certifying Commission in Medical Management, and is a Fellow of the American College of Military Public Health. After assignments at Fort Detrick, Fort Knox, and SHAPE, Belgium, COL(R) Hack then served as the Command Surgeon for the US Army Central Command-Kuwait from 2001 to 2002 (arriving in theater the day before 9/11) where he directed medical care for the US military in Kuwait, Saudi Arabia, and Qatar. He also served as Deputy Commander for Clinical Services for 3rd MEDCOM, assisting with planning medical support for Operation Enduring Freedom and providing clinical oversight over medical operations in Afghanistan and Pakistan. From 2008 to 2014, COL(R) Hack was the Director of the Combat Casualty Care Research Program (CCCRP) where he led trauma research across the Department of Defense, with a focus on Traumatic Brain Injury (TBI). He oversaw 650 TBI research projects and over $850 million in federal funds for TBI research. COL(R) Hack helped establish the 2013 National Research Action Plan on TBI and PTSD, the Chronic Effects of Neurotrauma Consortium, and the NCAA-DoD Grand Alliance. About Odyssey Group International, Inc.Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. For more information, visit: http://www.odysseygi.com About PRV-002 PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Forward-Looking StatementsThis news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions. CONTACT: Investor Contact: Rich Cockrell CG CAPITAL ODYY@CG.CAPITAL 404.736.3838

  • Odyssey Group International Welcomes World Cup Winner Abby Wambach to Sports Advisory Board
    GlobeNewswire

    Odyssey Group International Welcomes World Cup Winner Abby Wambach to Sports Advisory Board

    Wambach joins a growing team assembled to increase awareness regarding the unmet medical need for a treatment for brain injuries including concussionIrvine, CA, March 30, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is honored to welcome retired United States National Soccer Team captain Abby Wambach to its Sports Advisory Board (SAB). The inaugural members of the SAB include notable professional athletes who have a passion to advance treatments for brain injuries. Wambach is a two-time Olympic gold medalist, World Cup champion, and winner of the FIFA World Player of the Year. A six-time winner of the U.S. Soccer Athlete of the year, she is the record goal scorer for both the Men’s and Women’s National Soccer Teams. Internationally, Wambach is the second highest goal scorer of all time. Wambach joins the growing SAB team that crosses sporting boundaries and includes Brett Favre, Kurt Warner, Steve Mariucci, Mark Rypien and Chicago Cubs manager David Ross. The SAB will support Odyssey’s outreach efforts to enhance public awareness of traumatic brain injuries and concussion as well as the need for an FDA approved treatment. The Company is in the pre-clinical phase of development of a drug compound (PRV-002) and is currently preparing for its first human clinical trial. Michael Redmond, CEO of Odyssey said, “We are honored to have Abby join our Sports Advisory Board. She is a proven leader and an icon for women, athletes, and fans worldwide. Abby also understands the urgency and importance of the SAB’s mandate. Concussion is a major health issue that affects many facets of our population. With the SAB’s work and the development of PRV-002, we will be able to positively impact outcomes for concussion patients worldwide.” Wambach added, “I’m thrilled to be involved in such an important project. Concussion is a significant medical issue that needs a proven treatment. I’m hopeful that PRV-002 can provide this unmet need and am happy to be associated with this effort.” About Odyssey Group International, Inc.Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. For more information, visit: http://www.odysseygi.com About PRV-002PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Forward-Looking StatementsThis news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions. CONTACT: Media and Investors Contacts: CG CAPITAL Rich Cockrell 877.889.1972 investorrelations@cg.capital

  • ACCESSWIRE

    Odyssey Group International to Present at Virtual Investor Summit on March 24, 2021 at 2:30 PM ET

    CEO Michael Redmond to Highlight the Company's Strategy in Developing and Acquiring Life-Saving Medical ProductsIRVINE, CA / ACCESSWIRE / March 22, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced that its CEO, Michael Redmond, will present live to an online audience at the Q1 Virtual Investor Summit being held March 23-25, 2021.